• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

22.71 -0.71 (-3.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 437,136
Open 23.70
Bid (Size) 21.44 (200)
Ask (Size) 24.76 (200)
Prev. Close 23.42
Today's Range 22.44 - 23.81
52wk Range 3.420 - 30.00
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
December 26, 2025
A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter. 
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
-6.7%
-6.7%
3 Month
+30.5%
+30.5%
6 Month
+68.3%
+68.3%
1 Year
+112.2%
+112.2%

More News

Read More
News headline image
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
Via Benzinga
News headline image
UroGen (URGN) Q3 2025 Earnings Call Transcript ↗
November 06, 2025
Via The Motley Fool
Topics Earnings
News headline image
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗
November 06, 2025
Via Chartmill
News headline image
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
November 06, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
November 06, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
November 04, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
October 30, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
October 27, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
October 24, 2025
Via Benzinga
News headline image
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
October 02, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
August 21, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q2 Revenue Rises 11% ↗
August 07, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat ↗
August 07, 2025
Via Chartmill
News headline image
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
August 07, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 05, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
July 29, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit
July 28, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
July 28, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit
July 21, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
3 Bullish Biotech Stocks With Explosive Growth Trends ↗
July 21, 2025
Via MarketBeat

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 22.71
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 01/02/26 04:00 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 820.52M
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 821M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap